Else Nutrition

ALT5 SIGMA (NASDAQ: ALTS) STOCK QUOTE

Last Trade: US$ 1.96 -0.06 -2.97
Volume: 52,382
5-Day Change: -13.27%
YTD Change: 250.00%
Market Cap: -

LATEST NEWS FROM ALT5 SIGMA

LAS VEGAS , July 12, 2024 /CNW/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on fintech and healthcare, confirmed today that, as of market open on Monday, July 15, 2024 , the Company's new name will be "ALT5 Sigma Corporation" and its Nasdaq common stock ticker symbol will change to "ALTS". This will replace the Company's current ticker symbol "JAN". Further, the Company's website address will... Read More
The board has approved a strategic review of the biotech assets and ALT5 Sigma being the core focus going forward The company is intending a name and stock symbol change to reflect this decision LAS VEGAS , July 10, 2024 /CNW/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on fintech and healthcare, has announced plans to enhance stockholder value through a visionary strategic realignment,... Read More
LAS VEGAS , June 26, 2024 /CNW/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, is pleased to announce that it has appointed Mr. Vay Tham as its Chief Revenue Officer and President of ALT5 Sigma, Inc., its wholly-owned subsidiary. Mr. Tham brings extensive experience in capital markets, particularly in technology sectors, spanning over 25 years. His career includes roles... Read More
LAS VEGAS , June 25, 2024 /CNW/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, announced today that its wholly-owned subsidiary, ALT5 Sigma, has launched its prepaid VISA ®️ Card as an extension to the previously announced ALT5 Settlement Platform. ALT5 continues to expand its digital fintech offering in the crypto world to provide functionality from traditional legacy... Read More
LAS VEGAS , June 13, 2024 /CNW/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, released today its wholly-owned subsidiary, ALT5 Sigma, transaction volume for April and May 2024 . According to the Company, ALT5 Sigma transaction volume reached US$289 million for the months of April and May 2024 combined, compared to US$151 million in transaction volume for the months of... Read More
LAS VEGAS , June 11, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, announced today that its wholly-owned subsidiary, ALT5 Sigma, has launched a new service named "ALT5 Settlement Platform" aimed at the untapped Global Digital Content Creation Market. According to JanOne, ALT5 Settlement Platform enables Digital Platforms with the ability... Read More
LAS VEGAS , June 3, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on healthcare and fintech, announced today that it has been added to the Russell Microcap ® Index. The Russell Microcap ® Index was launched on June 1, 2005 and measures the performance of the microcap segment of the US Equity market and consists of 1,000 securities, including Virgin Galactic HLDG, Skye... Read More
LAS VEGAS , May 28, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN) a multidisciplinary organization with a focus on healthcare and fintech, announced today that its Fintech subsidiary, ALT 5 Sigma, will be presenting at the iFX Expo, the World's largest online trading conference and tradeshow held on June 18 until June 20 in Limassol, Cyprus . https://cyprus2024.ifxexpo.com/ The iFX Expo brings together thousands of C-Level... Read More
LAS VEGAS , May 16, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN) announced today it has closed its previously announced acquisition of blockchain financial technology provider, ALT 5 Sigma Inc., and each of its wholly-owned subsidiaries. Launched in 2018, ALT 5 is a fintech that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT 5, through its... Read More
ALT 5's transactional processing volume exceeded $1.1 billion in calendar 2023, and over $450 million in Q1 2024 LAS VEGAS , May 10, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN) announced today that it has executed a Definitive Agreement to acquire blockchain financial technology provider, ALT 5 Sigma Inc., a Delaware corporation, and each of its wholly-owned subsidiaries. The transaction is anticipated to close the week... Read More
LAS VEGAS , March 15, 2024 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain , today announced that on March 13, 2024 it received a notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market Inc. ("Nasdaq") indicating that the Company had regained compliance with the minimum bid price... Read More
Chief Medical Officer Dr. Amol Soin will explain innovative approaches to pain management and JanOne's development of non-addicting treatments for pain LAS VEGAS , Sept. 21, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, will participate in investor sessions at the Dawson James Securities 8 th Annual... Read More
Chief Medical Officer Dr. Amol Soin will discuss innovative approaches to pain management and JanOne's development of non-addicting treatments for pain LAS VEGAS , Aug. 31, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, will participate in investor sessions at the H.C. Wainwright 25 th Annual Global... Read More
The Broad Patent Coverage is a Major Milestone for the Commercial Success of Jan123 LAS VEGAS , Aug. 29, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the visionary biotech company dedicated to discovering non-addictive treatments for pain, as well as causes of pain, has earned a US patent for its innovative formulation of low-dose naltrexone, Jan123, for treating pain. Jan123 is being developed to treat complex regional pain... Read More
Abstract explained Jan101's statistically significant reduction in pain and improvement in nerve conduction velocity in prior Phase II study. LAS VEGAS , Aug. 25, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, has won a prestigious "Best Abstract" award for reporting that JanOne's treatment for diabetic... Read More
LAS VEGAS , Aug. 22, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN) (the "Company"), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 899,348 shares of the Company's common stock (or prefunded warrants in lieu thereof) at a purchase price... Read More
LAS VEGAS , Aug. 18, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN) (the "Company"), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 899,348 shares of the Company's common stock (or prefunded warrants in lieu thereof) at a purchase price of... Read More
JAN101 Showed Statistically Significant Reduction in Pain and Improvement in Nerve Conduction Velocity in Prior Phase II study. LAS VEGAS , Aug. 18, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, will present prior data on Jan101's randomized double blind placebo-controlled trial in diabetic neuropathy... Read More
Patent filing marks another milestone in becoming a world leader in pain management LAS VEGAS , June 28, 2023 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a biopharmaceutical company that is developing multiple drugs to treat chronic diseases like Peripheral Artery Disease (PAD) and Complex Regional Pain Syndrome (CRPS), has just filed an international patent application for methods of using low dose naltrexone to treat... Read More
Company now has pathway toward formal drug application LAS VEGAS , April 18, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical innovator specializing in non-addicting painkillers and new treatments for the causes of pain, has completed a successful pre-IND meeting with the FDA regarding Jan123. Jan123 is the company's unique oral delivery of low dose naltrexone formulated to treat complex regional pain... Read More
LAS VEGAS , April 13, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), Dr. Amol Soin , Chief Medical Officer of JanOne, will be presenting at the Appalachian Region Spine and Pain Meeting in Sulfur Springs, West Virginia on Saturday, April 15 th on the topic of Innovation in Pain Medicine and will be discussing the drug development programs at JanOne. JanOne is a biotech company that is developing two different late-stage... Read More
LAS VEGAS , March 24, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today announced the closing of its previously announced registered direct offering of 361,000 shares of the Company's common stock at a purchase price of $1.17 per share of common stock priced at-the-market under Nasdaq rules. H.C.... Read More
Bonfiglio is known for raising capital, building start-ups, and leading successful biotech companies as CEO and COO. LAS VEGAS , March 23, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, announced the hiring of John N. Bonfiglio , PhD, as interim president of its JanOne Biotech subsidiary. JanOne Biotech... Read More
LAS VEGAS , March 23, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 361,000 shares of the Company's common stock at a purchase price of $1.17 per share of common stock in a registered direct... Read More
Sale reduces liabilities by $17.6 million and entails at least $24 Million in future payments LAS VEGAS , March 22, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, announced that on March 9, 2023 they entered into a Stock Purchase Agreement with VM7, a Delaware corporation, under which VM7 agreed to... Read More
JAN 123's in vitro study on low dose naltrexone vies for the Society's "Best Research Abstract of the Year" LAS VEGAS , Feb. 22, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, will present data on two of its investigational pharmaceutical compounds at the American Society of Interventional Pain... Read More
In meetings hosted by Nasdaq MarketSite, the company reviewed its drug development programs that fight the opioid crisis through pharmaceuticals that reduce pain without causing addiction. LAS VEGAS , Jan. 26, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), which develops treatments for underlying causes of severe pain and brings to market drugs that relieve pain without the risk of addiction, held meetings at New York's Nasdaq... Read More
The acquisition of Soin provides JanOne with its second, late stage clinical stage asset LAS VEGAS , Jan. 10, 2023 /PRNewswire/ -- JanOne Inc. ("JanOne") (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that it has completed the acquisition of Soin Therapeutics, LLC and its product, a patent-pending, novel formulation of low-dose naltrexone. This... Read More
GreenStockNews
The acquisition of Soin will provide JanOne with its second clinical stage product JanOne Inc. ("JanOne") (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that it has executed a term sheet to acquire Soin Therapeutics LLC and its product, a... Read More
ARCA Recycling, Inc. (ARCA), a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), unveiled a new logo that aligns its visual identity with the innovative and environmentally responsible services it offers. While ARCA's core mission to deliver best-in-class energy efficiency and environmental protection programs remains unchanged, the company has expanded its customer base in recent years. ARCA has significantly grown its... Read More
Recent Developments at the University of Iowa have Resulted in an Improved Formulation of JAN101 JanOne Inc. ("JanOne") (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that work has been completed by Dr. Maureen Donovan at the University of Iowa that will allow for an improved formulation of JAN101. JAN101 (formerly known as TV1001SR), is a... Read More
ARCA Recycling, Inc., (ARCA), a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), will open three new recycling centers in June and July of this year to support growth in its recycling business and to help ARCA better serve its customers across North America . The new recycling facilities are located in Kent, Washington , Tulare, California and Hainesport, New Jersey . The centers will create new local jobs in each... Read More
Issuance of U.S. Patent 11,247,902 B2 Further Bolsters JanOne Inc.'s Intellectual Patent Portfolio JanOne Inc. (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that a patent was issued that covers a method of improving nerve function using JAN101. JAN101 (formerly known as TV1001SR), is a potential treatment for peripheral artery disease (PAD), a... Read More
Sale of GeoTraq allows JanOne to focus on core business strategy JanOne Inc. (Nasdaq: JAN), announced today that it has sold substantially all of the assets, and none of the liabilities, of GeoTraq Inc. ("GeoTraq"), its wholly-owned subsidiary, to SPYR Technologies Inc. ("SPYR"). "We believe this transaction further allows us to focus on our main business," said Tony Isaac CEO of JanOne. "Right now, our priority is the... Read More
GreenStockNews
JanOne Inc. (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties - in an effort to further reduce the drug addiction epidemic - previously announced an option agreement for the rights to a novel strategy to reduce methamphetamine (meth) use by activating the... Read More
GreenStockNews
ARCA Recycling, Inc. , a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), was recently awarded a contract to provide appliance recycling services to customers of a major electric utility in Virginia and North Carolina . The program encourages the early retirement of low-efficiency refrigerators and freezers and will run... Read More
GreenStockNews
JanOne Inc. (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties - in an effort to further reduce the drug addiction epidemic - today announced an option agreement for the rights to a novel strategy to reduce methamphetamine (meth) use by activating the Translocator... Read More
GreenStockNews
ARCA Recycling, Inc., a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), launched two new appliance recycling programs in Northern California , with a focus on decreasing the release of greenhouse gas (GHG) and ozone-depleting emissions into the atmosphere. The primary goal of these programs is to prevent the release of... Read More
GreenStockNews
ARCA Recycling, Inc., a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), has seen major growth in its appliance replacement programs throughout the past 12 months, with the addition of new contracts signed this year that total more than $3 million . It is estimated that these new contracts could increase ARCA's revenue... Read More
GreenStockNews
ARCA Recycling, Inc., a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), recently opened a new recycling facility in Grand Rapids, Michigan to support its growth in the state. ARCA was recently awarded multiple contracts to provide appliance recycling services for major Michigan electric utilities through the end of 2022;... Read More
GreenStockNews
ARCA Recycling, Inc., a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), was recently awarded multiple contracts to operate appliance recycling programs in the state of Pennsylvania through 2026. ARCA Recycling works in partnership with several major electric utility companies in the state and ARCA aims to recycle over... Read More
GreenStockNews
ARCA Recycling, Inc., a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), opened a new appliance recycling center last month in Pennsauken, New Jersey . The center will process appliances collected through new programs with multiple electric utilities in the state. These new programs, launched in the second and third... Read More
GreenStockNews
JanOne Inc. (Nasdaq: JAN), a company that focuses on the development of treatments for conditions that cause severe pain – in conjunction with its continuing focus on the development of drugs with non-addictive, pain-relieving properties – today announced that it is revising its development strategy based on recent... Read More
GreenStockNews
JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that it has selected CPC Clinical Research (CPC), a full-service academic research organization (ARO), as manager for its upcoming Phase 2b... Read More
GreenStockNews
JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that its clinical packaging partner Xerimis has received the bottled clinical batch of JAN101 for the upcoming Phase 2b trial for treating... Read More
GreenStockNews
JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced its selection of Avania as its regulatory partner in the upcoming planned Phase 2b trial of lead product candidate JAN101 for treating Peripheral... Read More
JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the appointment of Nicholas E. Goeders , Ph.D. to its Scientific Advisory Board (SAB). Dr. Goeders is considered one of the world's leaders on the role of stress in drug addiction. Tony Isaac , President and Chief Executive Officer of JanOne,... Read More
GreenStockNews
JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that it has engaged the services of DC Consulting LLC, a strategy and management consulting firm specializing in government affairs, regulatory... Read More
JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the successful completion of Current Good Manufacturing Practices (CGMP) production of the first batch of JAN101 for its upcoming Phase 2b trial for treating Peripheral Artery Disease (PAD). The initial batch, produced by manufacturing partner... Read More
JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that is has entered into a definitive agreement to sell its legacy recycling subsidiary, ARCA Recycling, to Virland Johnson , JanOne's Chief Financial Officer, for an aggregate purchase price of approximately $25 million . The agreement follows... Read More
JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the closing of previously announced its securities offering with gross proceeds of $6.0 million . The registered direct offering resulted in the sale by the company of an aggregate of 571,428 shares of common stock to certain institutional... Read More
JanOne Inc. (NASDAQ: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 571,428 shares of its common stock at a price of $10.50 per share, pursuant to a registered direct offering. The gross proceeds of the... Read More

COPYRIGHT ©2022 GREEN STOCK NEWS